Genient Accelerates Clinical Genomics Push with AIT Biotech Alliance

Under this partnership, Genient will distribute AIT Biotech’s next-generation sequencing platforms and assays in India, including the abSEQ Genetic Sequencer and abTRON Intelligent Centre.

Noida-based biotech startup, Genient, has strengthened its position in India’s clinical genomics space through a leadership transition and a new exclusive distribution agreement with Singapore-based AIT Biotech, enabling wider access to advanced next-generation sequencing technologies and molecular diagnostics solutions.

Founded in 2017, Genient has evolved from a technology-focused enterprise into a specialised player in molecular diagnostics and clinical genomics.

The company has built capabilities spanning infectious disease diagnostics, oncology genomics, transplant immunology, and genomic research, catering to hospitals, laboratories, and academic institutions.

The company’s exclusive agreement with AIT Biotech was formalised in March 2026. Under this partnership, Genient will distribute AIT Biotech’s next-generation sequencing platforms and assays in India, including the abSEQ Genetic Sequencer and abTRON Intelligent Centre.

These technologies are designed to support high-throughput genomic analysis and clinical decision-making across areas such as oncology, infectious disease surveillance, and drug resistance profiling.

Moreover, a key development in this transition is the appointment of Brijesh Singh as Chief Executive Officer. With over two decades of experience in molecular diagnostics and prior leadership at Siemens Healthineers, Singh brings commercial and operational expertise to scale Genient’s diagnostics footprint.

His role complements Founder Director Anil Kumar’s background in technology and consulting, creating a leadership structure focused on aligning innovation with clinical application.

“The partnership with AIT Biotech is not a conventional distribution arrangement — it is a strategic commitment to bring ISO-certified, clinically validated NGS technology to Indian laboratories that have, for too long, had to work around the absence of such solutions. AIT Biotech’s platforms are proven, precise, and purpose-built for clinical environments. Our exclusive distribution mandate means we can now offer Indian hospitals, research institutions, and diagnostic chains a credible, supported, end-to-end genomics pathway — from sample to clinical insight. This is how we make genomics real for India,” stated Brijesh Singh, CEO, Genient.

Genient’s strategy, combining global partnerships with local deployment capabilities, aims to extend access to genomic diagnostics beyond major urban centres to district hospitals, regional cancer institutes, and public health laboratories.

With this approach, it seeks to make precision diagnostics more accessible and practical within diverse clinical settings.

Stay tuned for more such updates on Digital Health News